JSK THERAPEUTICS INC.
SANDY, UT · CIK 0001724999 · Biotech · Private
JS-K, a nitric oxide-releasing small molecule therapeutic that selectively targets malignant cells by exploiting glutathione S-transferase overexpression in cancer cells
- Grants
- $4.0M
- 3 awards
- Sector median: 1
- Raised
- $963K
- 1 Form D · Dec 2017
- 106 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201720182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Clinical Development of JS-K for the Treatment of Cancer | $999,183 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Development of JS-K for the Treatment of Cancer | $1,998,606 | |
| Private capital raised | Form D · SEC | $962,839 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Development of JS-K for the Treatment of Cancer | $999,423 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2764 | SAFI BIOTHERAPEUTICS INC | — | — |
| 2765 | NANOVALENT PHARMACEUTICALS INC | — | — |
| 2766 | Florey Biosciences, Inc. | — | $1.4M |
| 2767 | JSK THERAPEUTICS INC. | — | $963K |
| 2768 | Wave Bye Inc. | — | $852K |
| 2769 | DIAVACS, INC. | — | $850K |
| 2770 | OCEANYX PHARMACEUTICALS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Dr. Joseph NowoslawskiDirector · Executive Officer
- Jason OckeyDirector
- Dinesh PatelDirector
- Randall PetersonDirector
- Paul ShamiDirector · Executive Officer
Patents
- Composition And Method For Topical Js-k As Therapy For Actinic Keratosisapplication
- Composition And Method For Topical Js-k As Therapy For Actinic Keratosisapplication
- Topical Js-k As Therapy For Actinic Keratosisapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.